NCT01647945View on ClinicalTrials.gov

FK506 (Tacrolimus) in Pulmonary Arterial Hypertension

PHASE2CompletedINTERVENTIONAL
Enrollment

23

Participants

Timeline

Start Date

July 31, 2012

Primary Completion Date

May 31, 2014

Study Completion Date

August 31, 2014

Conditions
Pulmonary Arterial Hypertension
Interventions
DRUG

Placebo

placebo pill

DRUG

FK506 level < 2 ng/ml

FK506 goal trough blood level \< 2 ng/ml

DRUG

FK506 level 2-3 ng/ml

FK506 goal trough blood level 2-3 ng/ml

DRUG

FK506 level 3-5 ng/ml

FK506 goal trough blood level 3-5 ng/ml

Trial Locations (1)

94305

Stanford University, Stanford

All Listed Sponsors
collaborator

Stanford University

OTHER

lead

Edda Spiekerkoetter

OTHER

NCT01647945 - FK506 (Tacrolimus) in Pulmonary Arterial Hypertension | Biotech Hunter | Biotech Hunter